Effects of Sodium-Glucose Cotransporter-2 (SGLT-2) Inhibitors on Health-Related Quality of Life and Exercise Capacity in Heart Failure Patients With a Preserved Ejection Fraction: A Scoping Review.
鈉-葡萄糖共轉運蛋白-2 (SGLT-2) 抑制劑對心衰竭患者(保留射血分數)健康相關生活品質和運動能力的影響:一項範疇回顧。
Cureus 2024-11-28
[European Society of Cardiology (ESC) guidelines on atrial fibrillation 2024 : What is new and what is important?].
2024 年歐洲心臟病學會 (ESC) 心房顫動指引:有什麼新內容及重要事項?
Herz 2024-11-28
Early combination therapy with SGLT2i and GLP-1 RA or dual GIP/GLP-1 RA in type 2 diabetes.
早期聯合治療 SGLT2i 和 GLP-1 RA 或雙重 GIP/GLP-1 RA 在第二型糖尿病中的應用。
Diabetes Obes Metab 2024-11-28
Three decades of glucose-lowering therapy in patients at high cardiovascular risk - A real-world analysis.
三十年來高心血管風險患者的降糖療法 - 一項真實世界分析。
Diabetes Obes Metab 2024-11-28
International Consensus Statement on Platelet Function and Genetic Testing in Percutaneous Coronary Intervention: 2024 Update.
經皮冠狀動脈介入治療中血小板功能與基因檢測的國際共識聲明:2024年更新。
JACC Cardiovasc Interv 2024-11-27
A Systematic Review and Meta-analysis on the Safety and Efficacy of Sodium-Glucose Cotransporter 2 Inhibitor Use in Hospitalized Patients.
住院病人使用鈉-葡萄糖共轉運蛋白 2 抑制劑的安全性和療效的系統性回顧與統合分析。
Diabetes Care 2024-11-27
Prescription Fills Among Patients With Type 2 Diabetes After Hospitalization for Acute Coronary Syndrome.
急性冠狀動脈綜合症住院後2型糖尿病患者的處方藥填寫情況。
JAMA Netw Open 2024-11-27
Semaglutide and the risk of adverse liver outcomes in patients with nonalcoholic fatty liver disease and type 2 diabetes: a multi-institutional cohort study.
Semaglutide 與非酒精性脂肪肝疾病及第二型糖尿病患者不良肝臟結果風險的關聯:一項多機構隊列研究。
Hepatol Int 2024-11-27
SGLT2 inhibitors in the prevention of diabetic cardiomyopathy: Targeting the silent threat.
SGLT2 抑制劑在預防糖尿病性心肌病中的應用:針對這一隱形威脅。
World J Cardiol 2024-11-27